

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: _____ Signature: _____
(Janice Roussel)

Docket No.: 0102286.00154US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of:
Piotr GRACZYK et al.

Application No.: 10/509128

Confirmation No.: 4053

Filed: September 28, 2004

Art Unit: 1614

For: 7-AZAINDOLES AS INHIBITORS OF C-JUN
N-TERMINAL KINASES FOR THE
TREATMENT OF NEURODEGENERATIVE
DISORDERS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Dated: *May 3, 2006*

Respectfully submitted,

By *Hollie L. Baker*

Hollie L. Baker

Registration No.: 31,321

WILMER CUTLER PICKERING HALE AND
DORR LLP

60 State Street

Boston, Massachusetts 02109

(617) 526-6000

Attorney for Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/509128-Conf. #4053
				Filing Date	September 28, 2004
				First Named Inventor	GRACZYK
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	0102286.00154US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP-0 737 685	10-16-1996	Viaud et al.		
	BB	EP-1 106 621	06-13-2001	Fuji Photo Film Co., Ltd.		
	BC	WO-99/20624	04-29-1999	Hoffmann-La Roche		
	BD	WO-99/21859	05-06-1999	Glaxo Group Limited		
	BE	WO-00/35909	06-22-2000	Hoffman-LaRoche		
	BF	WO-00/35921	06-22-2000	Hoffman-LaRoche		
	BG	WO-00/56710	09-28-2000	Glaxo Group Limited		
	BH	WO-00/64872	11-02-2000	Vertex Pharmaceuticals Inc.		
	BI	WO-01/12609	02-22-2001	Signal Pharmaceuticals, Inc.		
	BJ	WO-01/47922	07-05-2001	Aventis Pharma Limited		
	BK	WO-01/49288	07-12-2001	Merck Frosst Canada & Co.		
	BL	WO-02/16359	02-28-2002	Glaxo Group Limited		
	BM	WO-02/081475	10-17-2002	Eisai Co., Limited		
	BN	WO-03/082869	10-09-2003	Eisai London Research Laboratories Limited		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	CAO et al., "Distinct Requirements for p38 α and c-Jun N-terminal Kinase Stress-activated Protein Kinases in Different Forms of Apoptotic Neuronal Death", <i>The Journal of Biological Chemistry</i> , Vol. 279, No. 34, pp. 35903-35913, 20 August 2004	
	CB	EILERS et al., "Direct Inhibition of c-Jun N-terminal Kinase in Sympathetic Neurones Prevents c-jun Promoter Activation and NGF Withdrawal-induced Death", <i>Journal of Neurochemistry</i> , Vol. 76, pp. 1439-1454, 2001	
	CC	EILERS et al., "Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons", <i>The Journal of Neuroscience</i> , Vol. 18, No. 5, pp. 1713-1724, 1 March 1998	
	CD	ESTUS et al., "Aggregated Amyloid- β Protein Induces Cortical Neuronal Apoptosis and Concomitant "Apoptotic" Pattern of Gene Induction", <i>The Journal of Neuroscience</i> , Vol. 17, No. 20, pp. 7736-7745, 15 October 1997	
	CE	HAM et al., "A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

5450114

US1DOCS 5450114v1



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/509128-Conf. #4053
				Filing Date	September 28, 2004
				First Named Inventor	GRACZYK
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	0102286.00154US1

		Programmed Cell Death", <i>Neuron</i> , Vol. 14, pp. 927-939, May, 1995	
	CF	HARPER et al., "Inhibitors of the JNK Signaling Pathway", <i>Drugs of the Future</i> , Vol. 26, No. 10, pp. 957-973, 2001	
	CG	LISNOCK et al., "Activation of JNK3 α 1 Requires Both MKK4 and MKK7: Kinetic Characterization of in Vitro Phosphorylated JNK3 α 1", <i>Biochemistry</i> , Vol. 39, pp. 3141-3149, 2000	
	CH	WATSON et al., "Phosphorylation of c-Jun is Necessary for Apoptosis Induced by Survival Signal Withdrawal in Cerebellar Granule Neurons", <i>The Journal of Neuroscience</i> , Vol. 18, No. 2, pp. 751-762, 15 January 1998	
	CI	YOUNG et al., "Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site", <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 18, pp. 12116-12121, 2 May 1997	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

5450114

US1DOCS 5450114v1



IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/509128-Conf. #4053
Filing Date	September 28, 2004
First Named Inventor	Piotr GRACZYK
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	0102286.00154US1

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	(1) PTO Form SB/08;
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	(2) 23 non-US patent references;
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	(3) Return Postcard.
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP		
Signature	<i>Hollie L. Baker</i>		
Printed name	Hollie L. Baker		
Date	<i>May 3, 2006</i>	Reg. No.	31,321

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: *May 3, 2006* Signature: *Janice Roussel* (Janice Roussel)